Medical Physicist | Biophysiker/in

EBG MedAustron GmbH

Wiener Neustadt, Niederösterreich, Österreich
Published Mar 4, 2026
Full-time
Permanent

Job Summary

As a Medical Physicist specializing in beam delivery and expansion projects, you will play a critical role in advancing cancer treatment using a particle accelerator. Based at MedAustron, you will work with a synchrotron delivering protons and carbon ions, specifically contributing to the development of a new compact proton therapy system. Your daily responsibilities include designing and implementing an integrative Quality Assurance (QA) framework, supporting dosimetry activities, and performing routine QA shifts to ensure patient safety. You will act as a vital bridge between current clinical systems and next-generation therapy technologies. This role is highly interdisciplinary, requiring you to drive tasks across departments and collaborate with a diverse team of experts. The position offers a unique opportunity to work directly with cutting-edge medical hardware and software-driven QA workflows in a permanent, full-time capacity starting in June 2026, making it an ideal role for those dedicated to clinical innovation and technical excellence.

Required Skills

Education

Master's degree or PhD in Medical Physics, Biomedical Engineering, or a similar field. Medical Physics certification is advantageous but not essential.

Experience

  • Professional experience in Medical Physics with a focus on dosimetry and ion beam therapy
  • Experience with QA automation and software-supported QA tools
  • Hands-on experience with the acceptance and commissioning of complex medical devices
  • Experience working with various vendors of particle accelerators and dosimetry equipment
  • Proven track record of self-driven project work and autonomous task delivery

Languages

German (Basic)English (Fluent)

Additional

  • Willingness to work in shifts is required. The position is based in a multidisciplinary and intercultural environment. Must be able to start by June 2026.